JCI Insight (Jul 2022)

EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia

  • Magdalena L. Bochenek,
  • Rajinikanth Gogiraju,
  • Stefanie Großmann,
  • Janina Krug,
  • Jennifer Orth,
  • Sabine Reyda,
  • George S. Georgiadis,
  • Henri M. Spronk,
  • Stavros Konstantinides,
  • Thomas Münzel,
  • John H. Griffin,
  • Philipp Wild,
  • Christine Espinola-Klein,
  • Wolfram Ruf,
  • Katrin Schäfer

Journal volume & issue
Vol. 7, no. 14

Abstract

Read online

Blood clot formation initiates ischemic events, but coagulation roles during postischemic tissue repair are poorly understood. The endothelial protein C receptor (EPCR) regulates coagulation, as well as immune and vascular signaling, by protease activated receptors (PARs). Here, we show that endothelial EPCR-PAR1 signaling supports reperfusion and neovascularization in hindlimb ischemia in mice. Whereas deletion of PAR2 or PAR4 did not impair angiogenesis, EPCR and PAR1 deficiency or PAR1 resistance to cleavage by activated protein C caused markedly reduced postischemic reperfusion in vivo and angiogenesis in vitro. These findings were corroborated by biased PAR1 agonism in isolated primary endothelial cells. Loss of EPCR-PAR1 signaling upregulated hemoglobin expression and reduced endothelial nitric oxide (NO) bioavailability. Defective angiogenic sprouting was rescued by the NO donor DETA-NO, whereas NO scavenging increased hemoglobin and mesenchymal marker expression in human and mouse endothelial cells. Vascular specimens from patients with ischemic peripheral artery disease exhibited increased hemoglobin expression, and soluble EPCR and NO levels were reduced in plasma. Our data implicate endothelial EPCR-PAR1 signaling in the hypoxic response of endothelial cells and identify suppression of hemoglobin expression as an unexpected link between coagulation signaling, preservation of endothelial cell NO bioavailability, support of neovascularization, and prevention of fibrosis.

Keywords